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Fig. 1. (A) Two circumscribed mor-
phea on the right and left sides of 
the back. (B) Linear scleroderma on 
the left side of the forehead. (C) 
Vitiliginous lesions on the left side 
of the trunk.
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Dear Editor:
A 10-year-old girl presented with a round, brown to whit-
ish, atrophic plaque on the right side of her back, which 
she has had for 5 years. Histologic findings showed thick 
collagen bundles with lymphocytic infiltrations around the 
vessel in the dermo-subcutaneous tissue, which are con-
sistent with morphea. Only topical calcipotriol was used 
due to the limited localization of the plaque and the 
young age of the patient. However, after 6 months, a new 
morphea lesion developed on the left side of the back and 
linear scleroderma occurred on the forehead. The patient 
was diagnosed with generalized mixed-type morphea, 
with two circumscribed morphea on the right and left 
sides of the back (Fig. 1A) and linear scleroderma on the 
forehead (Fig. 1B). Hypopigmented lesions were also pres-
ent on her left leg and on the left side of the trunk (Fig. 
Letter to the Editor
250 Ann Dermatol
Fig. 2. Flow diagram during the follow-up period. NBUVB: narrowband ultraviolet B.
1C). Based on Wood’s light examination and clinical find-
ings, the patient was diagnosed with segmental vitiligo 
(SV).
The vitiliginous lesions and linear scleroderma on the 
forehead showed progression despite the combination 
therapy using intermittent oral steroid, topical calcineurin 
inhibitor, and narrowband ultraviolet B phototherapy for 1 
year. To block the progression of morphea, hydroxy-
chloroquine sulfate (200 mg/day) was used. Skin lesions of 
morphea and vitiligo stabilized within 6 weeks. In addi-
tion, the vitiliginous lesions showed 70% repigmentation 
after 5 months from start of medication. Skin lesions of 
morphea also showed no more progression. The patient 
tolerated the 7-month treatment period with no side ef-
fects (Fig. 2).
Although the pathogenesis of vitiligo remains unknown, 
an immunological mechanism is strongly considered. 
However, SV is associated with a neurogenic mechanism. 
Furthermore, an immune-mediated mechanism known as 
the three-step theory has been reported to be involved in 
the pathogenesis of SV, according to a case report show-
ing simultaneous occurrence of SV, alopecia areata, psor-
iasis, and halo nevus1.
The association of SV with scleroderma has been rarely re-
ported2. Bonifati et al.3 reported the case showing linear 
scleroderma on the left limb and homolateral SV on the 
trunk. Contrary to previous reports, our patient had gener-
alized morphea lesions on the right and left sides of the 
back and linear scleroderma on the left side of the fore-
head, which was on the same side of the body where SV 
was located.
Our case study suggested that hydroxychloroquine is ef-
fective not only in blocking the progression of scle-
roderma4 but also in treating vitiligo. Walsh et al.5 re-
ported two systemic lupus erythematosus patients with ex-
tensive widespread vitiligo-like depigmentations who 
showed rapid responses to hydroxychloroquine.
Although we cannot exclude the possibility of coinci-
dental development of SV and scleroderma, our case sug-
gested that vitiligo and scleroderma that have the same au-
toimmune background can occur at the same time be-
cause they occurred during the same period and pro-
gressed in parallel for several years. In addition, this con-
comitant presence could support the theory that SV is as-
sociated with an autoimmune background. Moreover, our 
report suggested that an antimalarial drug could be used 
as a promising option for the treatment of vitiligo. 
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